Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HES-docetaxel
- Development stage
- Preclinical
- Lead developer
- Fresenius Kabi
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
HES-docetaxel is a polymer-drug conjugate consisting of the cytotoxic taxane docetaxel covalently coupled to hydroxyethyl starch (HES) via a cleavable linker. Developed by Fresenius Kabi, this conjugate is designed to improve the water solubility, tolerability, and pharmacokinetic profile of docetaxel. By utilizing HES as a macromolecular carrier, the conjugate avoids the need for irritating excipients (such as polysorbate 80) typically required to dissolve hydrophobic docetaxel, thereby reducing exposure peaks and improving safety. In preclinical models of breast cancer, HES-docetaxel demonstrated enhanced anti-tumor efficacy and superior tolerability compared to free docetaxel.
- Other names
- HES-docetaxel conjugatehydroxyethyl starch-docetaxelhydroxyethyl starch-docetaxel conjugate
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))PXR (Pregnane X receptor)ABCC10 (Multidrug resistance-associated protein 7)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on HES-docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HES-docetaxel.